{"article": [{"url": "https://www.marketwatch.com/story/quest-diagnostics-profit-falls-a-lost-less-than-expected-full-year-guidance-reinstated-2020-07-23", "published": 1595487920.0, "headline": "Quest Diagnostics profit falls a lost less than expected, full-year guidance reinstated", "body": "Shares of Quest Diagnostics Inc. DGX, +0.33% slipped 0.6% in premarket trading Thursday, although the provider diagnostic tests for the health care industry reported a second-quarter profit that fell a lot less than expected, as the rapid expansion of COVID-19 testing helped revenue beat forecasts, but provided an in-line outlook. Net income fell to $185 million, or $1.36 a share, from $226 million, or $1.66 a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share fell to $1.42 from $1.73 but was above the FactSet consensus of 64 cents. Revenue fell 6.4% to $1.83 billion but beat the FactSet consensus of $1.69 billion. The company said it reinstated its 2020 financial outlook, with guidance ranges for adjusted EPS of $6.60 to $8.60, compared with the FactSet consensus of $6.76, and for revenue of $8.0 billion to $8.6 billion, surrounding expectations of $8.25 billion. The stock has rallied 21.5% year to date through Wednesday, while the S&P 500 SPX, +0.87% has gained 1.4%."}]}